Why Cardinal Health (CAH) is a Top Growth Stock for the Long-Term

Cardinal Health (CAH) is identified as a top growth stock, receiving a Zacks Rank #2 (Buy) and top-tier 'A' scores for both Growth and VGM. This positive outlook is driven by a projected 14.2% year-over-year earnings growth for the current fiscal year, alongside seven upward analyst revisions for fiscal 2026 estimates, which have raised the consensus to $9.41 per share, and a historical average earnings surprise of +9.2%. As a major global healthcare services and products provider, CAH's extensive market presence and strong financial indicators position it as a compelling investment.

Analysis

Cardinal Health (CAH) exhibits a strong quantitative profile, positioning it as a compelling growth opportunity according to the provided analysis. The company holds a Zacks Rank #2 (Buy), supported by top-tier 'A' scores for both Growth and overall VGM (Value, Growth, Momentum). This positive outlook is substantiated by a forecast for 14.2% year-over-year earnings growth in the current fiscal year. Analyst sentiment is notably bullish, with seven upward earnings estimate revisions for fiscal 2026 in the past 60 days, leading to a $0.20 increase in the consensus estimate to $9.41 per share. Furthermore, CAH has a demonstrated history of outperformance, with an average positive earnings surprise of 9.2%. The company's fundamental strength is rooted in its vast operational scale, serving nearly 90% of U.S. hospitals and operating diverse segments including pharmaceutical distribution, specialty solutions, and a significant network of nuclear pharmacies.

Key Decisions for Investors

• Given the combination of a Zacks #2 (Buy) rank, an 'A' Growth Score, and significant upward earnings estimate revisions, investors with a growth-focused strategy should consider CAH a strong candidate for inclusion in their portfolios.
• Monitor upcoming earnings reports to see if the company can sustain its track record of positive surprises and meet the high expectations set by the 14.2% projected earnings growth, as this is a key pillar of the current bullish thesis.
• While the quantitative signals are strong, it is prudent to conduct further due diligence on the fundamental drivers and competitive landscape within CAH's Pharmaceutical and Medical Products segments to validate the sustainability of this projected growth.